Celltrion's Zymfentra covers over 90% of US health insurance market
Celltrion, a major Korean pharmaceutical company, signed a contract with a U.S. group purchasing organization (GPO) to list Zymfentra, its autoimmune disease drug treatment, on private insurance formularies, the company said on Tuesday. This move is expected to expand the drug's coverage to over 90 percent of the U.S. health insurance market.
Oct 29, 2024By Nam Hyun-woo